Fulminant Eosinophilic Myocarditis After Sequential Biologic Therapy in Ulcerative Colitis Authors: Jinyoung Lee, Darae Kim, David Hong, Ji Hyun Cha, Kang Noeul, Jung-Sun Kim, Jeong Hoon Yang, Jin-Oh Choi Published: 2026 ABSTRACT AbstractBackgroundEosinophilic myocarditis has heterogeneous presentations and may cause fulminant cardiogenic shock.Case SummaryA 35-year-old man with ulcerative colitis and eosinophilia developed cardiogenic shock after sequential biologic therapy (most recently vedolizumab) and corticosteroid withdrawal. He rapidly deteriorated with severe biventricular dysfunction (left ventricular ejection fraction 10%) and hypereosinophilia (eosinophil count 2,154/μL). Coronary angiography showed no obstructive disease, and cardiac magnetic resonance suggested diffuse myocardial involvement. Endomyocardial biopsy confirmed eosinophilic myocarditis. He required veno-arterial extracorporeal membrane oxygenation and high-dose intravenous methylprednisolone. Recurrent eosinophilia during tapering prompted use of mepolizumab, followed by recovery of left ventricular function.DiscussionBiologic exposure with corticosteroid withdrawal was temporally associated with systemic eosinophilic activation, and histologic confirmation by biopsy enabled escalation to targeted therapy.Take-Home MessagesIn patients with inflammatory bowel disease receiving biologics, hypereosinophilia with acute heart failure should prompt evaluation for eosinophilic myocarditis. Early biopsy may enable timely escalation to targeted immunomodulatory therapy.Key words: cardiac assist devices, cardiomyopathy, hemodynamics History of Presentation A 35-year-old man with ulcerative colitis (UC) diagnosed 4 years earlier presented to a local clinic with dizziness and a mild fever (37.7 °C). He received symptomatic treatment, but symptoms persisted. Take-Home Messages •In patients with IBD receiving biologics, hypereosinophilia with acute heart failure should prompt evaluation for eosinophilic myocarditis. In patients with IBD receiving biologics, hypereosinophilia with acute heart failure should prompt evaluation for eosinophilic myocarditis. •Early biopsy may enable timely escalation to targeted immunomodulatory therapy. Early biopsy may enable timely escalation to targeted immunomodulatory therapy. After 3 days, the patient presented to a local emergency department. Initial laboratory testing showed abnormal liver enzymes, impaired renal function, and elevated cardiac biomarkers, including creatine kinase-MB and troponin T. Transthoracic echocardiography demonstrated increased left ventricular wall thickness suggestive of myocardial edema with reduced left ventricular systolic function (left ventricular ejection fraction 20%). He experienced rapid clinical deterioration and suspected acute myocarditis complicated by shock and was transferred to our coronary care unit. On arrival, laboratory tests showed elevated liver enzymes (total bilirubin 0.5 mg/dL, aspartate aminotransferase 239 U/L, alanine aminotransferase 410 U/L, alkaline phosphatase 139 U/L), and impaired renal function (blood urea nitrogen 37.4 mg/dL, creatinine 1.59 mg/dL). Cardiac biomarkers were further elevated (creatine kinase-MB 30.7 ng/mL, troponin T 2.200 ng/mL) (Figure 1A). The eosinophil fraction was 11.8% with an absolute eosinophil count of 2,154/μL. Chest radiography showed mild pulmonary edema without cardiomegaly, and electrocardiography demonstrated sinus tachycardia (Figures 1B and 1C). Clinical Course and Multimodality Cardiac Imaging Findings (A) Serial changes in cardiac biomarkers. (B) Electrocardiography. (C) Chest radiography. (D) Cardiac magnetic resonance showing diffuse myocardial thickening with mild late gadolinium enhancement. CK-MB = creatine kinase-MB; NT-proBNP = N-terminal pro–B-type natriuretic peptide. Repeat transthoracic echocardiography on admission revealed severe biventricular systolic dysfunction and a markedly thickened left ventricular wall (posterior wall thickness 1.63 cm, septal wall thickness 1.50 cm), consistent with diffuse myocardial edema. Given cardiogenic shock with multiorgan dysfunction, veno-arterial extracorporeal membrane oxygenation (VA-ECMO) was initiated as a bridge to recovery. Past Medical History and Medication History at Presentation The patient had been diagnosed with UC in April 2021 after presenting with hematochezia. Initial therapy included oral prednisolone and mesalazine; azathioprine was added in December 2021 for inadequate disease control. He remained clinically stable until July 2023, when UC activity worsened and intravenous infliximab (tumor necrosis factor alpha [TNF–α] inhibitor) was initiated, and previous therapy was continued. He received 37 infliximab infusions through January 2025, when cough and chest tightness developed with suspected drug-induced asthma; infliximab was discontinued. Owing to a subsequent flare of UC, upadacitinib (Janus kinase inhibitor) was initiated in January 2025; however, chest tightness recurred shortly after initiation, and the drug was discontinued. In March 2025, vedolizumab (gut-selective α4β7 integrin inhibitor) was initiated. He received 4 infusions, with the last one administered in September 2025, approximately 1 month before the current presentation. He had no prior history of ischemic heart disease, cardiomyopathy, or known structural heart disease. Differential Diagnosis In the setting of cardiogenic shock with biventricular failure, elevated cardiac biomarkers, and hypereosinophilia, acute myocarditis was the leading diagnosis. Acute coronary syndrome without obstructive disease and stress-induced cardiomyopathy were considered given the abrupt clinical deterioration. Fulminant myocarditis of infectious or immune-mediated etiology was also considered. In addition, parasitic infection and eosinophilic granulomatosis with polyangiitis was considered in the differential diagnosis because of marked eosinophilia. However, given recent biologic exposure and marked eosinophilia, eosinophilic myocarditis, including drug-related hypersensitivity, was strongly suspected. Investigations Given the presence of cardiogenic shock with marked hypereosinophilia and suspected myocarditis, we evaluated both secondary causes of eosinophilia and the etiology of acute heart failure. Serologic testing for systemic vasculitis, connective tissue disease, and parasitic infection was performed. Fluorescent antinuclear antibody, antineutrophil cytoplasmic antibody, and parasite-specific antibody tests were negative. Toxocara canis immunoglobulin G and stool ova and parasite examination were also negative. Total immunoglobulin E was elevated (340 kU/L). The soluble interleukin-2 receptor level was elevated (2,901.6 pg/mL; reference range 175.3-858.2 pg/mL), indicating immune activation. Coronary angiography demonstrated no significant coronary artery stenosis. Cardiac magnetic resonance showed mild diffuse late gadolinium enhancement, consistent with active myocarditis (Figure 1D). A next-generation sequencing cardiomyopathy panel (33 genes) identified no pathogenic or likely pathogenic variants. Endomyocardial biopsy revealed dense myocardial infiltration by eosinophils, confirming eosinophilic myocarditis (Figure 2A). Serial Endomyocardial Biopsy Findings (A) Initial endomyocardial biopsy specimen obtained at the time of cardiogenic shock. A large number of eosinophils with coarse red cytoplasmic granules (yellow arrows) are infiltrating the myocardium as well as the endocardium. Eosinophilic infiltration is diffuse and not limited to the perivascular area. (B) Follow-up endomyocardial biopsy specimen after veno-arterial extracorporeal membrane oxygenation removal. A small amount of mixed inflammatory cells is present mainly in the endocardium, with a few eosinophils (yellow arrows), suggesting the resolving phase of eosinophilic myocarditis. Management The patient was supported with VA-ECMO for cardiogenic shock with multiorgan dysfunction. On the day after VA-ECMO initiation, he developed refractory ventricular arrhythmias requiring external defibrillation and continuous intravenous amiodarone and esmolol infusions. As pulmonary edema worsened, left atrial venting was performed to facilitate decongestion. Endomyocardial biopsy confirmed eosinophilic myocarditis with dense eosinophilic myocardial infiltration. High-dose intravenous methylprednisolone was administered (500 mg daily for 3 days) followed by oral prednisolone (20 mg daily) with a structured taper. During dose reduction, eosinophil counts rose again. To reassess for persistent eosinophilic myocardial inflammation and to exclude an alternative inflammatory etiology not captured on the initial biopsy, repeat endomyocardial biopsy was performed. Although myocardial eosinophilic infiltration decreased substantially, focal eosinophils persisted; therefore, anti–interleukin-5 therapy (mepolizumab) was administered. Although mepolizumab 300 mg is commonly used in hypereosinophilic syndrome, 100 mg was selected in this case as a pragmatic off-label dose based on local clinical practice and accessibility. The primary goal was steroid-sparing control of recurrent eosinophilia, and the patient showed subsequent stabilization and improvement. Outcome and Follow-Up With improvement in ventricular function, VA-ECMO was successfully weaned. During corticosteroid tapering, peripheral eosinophil counts rose again and clinical recovery plateaued. To reassess myocardial inflammation, repeat endomyocardial biopsy was performed. Despite prior pulse corticosteroid therapy, repeat biopsy showed a substantial reduction in myocardial eosinophilic infiltration; however, persistent focal eosinophils remained, suggesting an incomplete tissue response to corticosteroids (Figure 2B). Given recurrent peripheral eosinophilia despite ongoing corticosteroid therapy, subcutaneous mepolizumab 100 mg was administered. The patient subsequently stabilized and was transferred to the general ward. Follow-up echocardiography performed 2 days before discharge demonstrated recovery of left ventricular systolic function (left ventricular ejection fraction 61%). Discussion Patients with inflammatory bowel disease (IBD) have been reported to have an increased long-term risk of myocarditis compared with the general population.1 Also, population-based data in UC and Crohn’s disease suggest that this complication, although rare, can be clinically significant. Moreover, a multiyear study in a large IBD cohort suggested that peripheral blood eosinophilia may serve as a biomarker of a distinct IBD subgroup with a unique inflammatory signature and a higher risk of adverse clinical outcomes.2 In the present case, the patient had no history of asthma or other atopic disease, but exhibited chronic mild peripheral eosinophilia even before the diagnosis of UC, suggesting a predisposition to eosinophil-driven immune activation (Figure 3A). Notably, peripheral eosinophil counts began to rise approximately 2 months after initiation of infliximab (Figure 3B). After vedolizumab initiation and withdrawal of systemic corticosteroids, eosinophilia progressed further, reaching 2,154/μL at the time eosinophilic myocarditis was histologically confirmed. Temporal Changes in Peripheral Eosinophil Count (A) Absolute eosinophil count before admission. Progressive elevation of the peripheral eosinophil count was observed before hospitalization and was temporally associated with recent biologic therapy exposure. (B) Dynamic changes in eosinophil count following immunosuppressive therapy. Marked eosinophilia at presentation rapidly declined after initiation of high-dose corticosteroid therapy and targeted anti–interleukin-5 treatment. UC = ulcerative colitis. TNF-α is implicated in eosinophil recruitment and activation. Although TNF-α inhibition would be expected to attenuate eosinophil-mediated inflammation, paradoxical eosinophilia and eosinophilic organ involvement have been described during anti–TNF-α therapy.3 Reports in IBD cohorts and case reports have documented peripheral eosinophilia and eosinophil-predominant pulmonary or gastrointestinal manifestations during infliximab treatment4 Vedolizumab is a gut-selective humanized monoclonal antibody targeting the α4β7 integrin and disrupts leukocyte trafficking to the intestinal mucosa via the α4β7/MAdCAM-1 pathway. Emerging clinical observations have suggested that α4β7 blockade may be associated with peripheral hypereosinophilia and eosinophil-mediated extraintestinal injury in susceptible patients.5 Although mechanistic data in humans remain limited, these reports raise the possibility that altered gut-specific homing may shift eosinophilic inflammation beyond the intestine. High-dose corticosteroids are generally associated with rapid clinical and hematologic improvement in eosinophilic myocarditis.6 However, steroid responsiveness is heterogeneous, and persistent or recurrent eosinophilia during tapering has been reported in a subset of patients.7 In such cases, ongoing systemic eosinophilic activation may not be adequately controlled by corticosteroids alone, despite partial improvement in myocardial inflammation. Targeted immunomodulatory therapies directed against eosinophil survival pathways, including interleukin-5 inhibition, have been increasingly used in steroid-refractory eosinophilic disorders. Although evidence in eosinophilic myocarditis remains limited to case reports and small series, these agents may offer a rational steroid-sparing option when eosinophilia persists or recurs despite adequate corticosteroid therapy.8,9 In our patient, recurrent peripheral eosinophilia during tapering together with incomplete tissue response on repeat biopsy supported escalation to anti–interleukin-5 therapy. In this context, our case supports a temporal association between sequential biologic exposure, corticosteroid withdrawal, and progressive hypereosinophilia preceding fulminant eosinophilic myocarditis. Importantly, endomyocardial biopsy, rather than imaging alone, provided a definitive etiologic diagnosis and enabled escalation to targeted immunomodulatory therapy when eosinophilia recurred during corticosteroid tapering. This diagnostic and therapeutic pathway may be particularly relevant in patients with IBD receiving biologic therapy who develop acute heart failure with hypereosinophilia. In this setting, close monitoring of eosinophil trends and early consideration of endomyocardial biopsy can facilitate timely escalation to targeted immunomodulatory therapy.10 Conclusions This case highlights that eosinophilic myocarditis in patients with IBD can manifest with fulminant cardiogenic shock requiring temporary mechanical circulatory support. Despite high-dose corticosteroid therapy, systemic eosinophilic activity may persist or recur, underscoring the value of endomyocardial biopsy for etiologic confirmation. In refractory or relapsing courses, escalation to targeted immunomodulatory therapy, including anti–interleukin-5 treatment, may be considered as a steroid-sparing strategy. Visual SummaryCase TimelineTimelineEventsDay 1The patient was transferred to our tertiary center with cardiogenic shock, severe left ventricular dysfunction, edematous left ventricular wall thickening, elevated cardiac biomarkers, and multiorgan injury.Day 2Coronary angiography showed no significant stenosis, and veno-arterial extracorporeal membrane oxygenation was initiated for progressive shock.Day 4Endomyocardial biopsy confirmed eosinophilic myocarditis. High-dose intravenous methylprednisolone pulse therapy was started. Recurrent ventricular tachycardia required defibrillation and antiarrhythmic therapy.Day 5Transseptal left atrial venting was performed for worsening pulmonary edema.Day 7Peripheral eosinophilia resolved, and corticosteroids were tapered.Day 15Heart transplantation work-up was initiated because of delayed clinical recovery despite steroid therapy and difficulty weaning from veno-arterial extracorporeal membrane oxygenation.Day 20Cardiac function gradually improved, and the patient tolerated minimal veno-arterial extracorporeal membrane oxygenation support.Day 22Left ventricular function gradually improved, allowing successful veno-arterial extracorporeal membrane oxygenation removal.Day 23Repeat endomyocardial biopsy showed residual eosinophilic infiltration, and mepolizumab was administered.Day 35Echocardiography showed normalized left ventricular systolic function and improved left ventricular wall thickening.Day 37The patient was discharged on tapering oral prednisolone and mepolizumab. Case Timeline Funding Support and Author Disclosures The authors have reported that they have no relationships relevant to the contents of this paper to disclose. Footnotes The authors attest they are in compliance with human studies committees and animal welfare regulations of the authors’ institutions and Food and Drug Administration guidelines, including patient consent where appropriate. For more information, visit the Author Center. References